Desensitization of central cholinergic mechanisms and neuroadaptation to nicotine.
This review focuses on neuroadaptation to nicotine. The first part of the paper delineates some possible general mechanisms subserving neuroadaptation to commonly abused drugs. The postulated role of the mesocorticolimbic neuroanatomical pathway and drug-receptor desensitization mechanisms in the establishment of tolerance to, dependence on, and withdrawal from psychoactive drugs are discussed. The second part of the review deals with the pharmacological effects of nicotine at both pre- and postsynaptic locations within the central nervous system, and the still-perplexing upregulation of brain nicotine-binding sites seen after chronic nicotine administration. A special emphasis has been put on desensitization of presynaptic cholinergic mechanisms, and postsynaptic neuronal nicotinic-receptor function and its modulation by endogenous substances. A comparison with the inactivation process occurring at peripheral nicotinic receptors is also included. Finally, a hypothesis on the possible connections between desensitization of central cholinergic mechanisms and neuroadaptation to nicotine is advanced. A brief comment on the necessity of fully understanding the effects of nicotine on the developing nervous system closes this work.
Ochoa
E L
EL
Department of Pediatrics, School of Medicine, University of California, Davis 95616.
Li
L
L
McNamee
M G
MG
D000222:Adaptation, Physiological; D000818:Animals; D001338:Autonomic Fibers, Postganglionic / Q000187:drug effects; D001339:Autonomic Fibers, Preganglionic / Q000187:drug effects; D016739:Behavior, Addictive / Q000503:physiopathology; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D002038:Bungarotoxins / Q000494:pharmacology; D002799:Cholinergic Fibers / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism / Q000502:physiology; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008032:Limbic System / Q000187:drug effects / Q000503:physiopathology; D008954:Models, Biological; D009420:Nervous System / Q000187:drug effects / Q000196:embryology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009538:Nicotine / Q000009:adverse effects / Q000494:pharmacology* / Q000633:toxicity; D009714:Nucleus Accumbens / Q000187:drug effects / Q000503:physiopathology; D010947:Plants, Toxic; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000502:physiology; D012201:Reward; D015398:Signal Transduction; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000209:etiology / Q000503:physiopathology; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D014026:Nicotiana; D015854:Up-Regulation / Q000187:drug effects
D002038:Bungarotoxins; D011978:Receptors, Nicotinic; D009538:Nicotine; D004298:Dopamine